EcoDrugPlus

Phosphodiesterase 4c

Ensembl ID : ENSBBBG00000001877
Gene Symbol: PDE4C
3 Cross references
88 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSBBBG00000003548
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSBBBG00000005825
Gene Symbol: PDE5A
3 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSBBBG00000008657
Gene Symbol: PDE7A
3 Cross references
240 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSBBBG00000006552
Gene Symbol: PDE7B
3 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSBBBG00000014410
Gene Symbol: PDE9A
3 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSBBBG00000013088
Gene Symbol: PIK3R1
3 Cross references
259 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSBBBG00000010787
Gene Symbol: PIK3R2
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSBBBG00000015789
Gene Symbol: PIK3R3
3 Cross references
276 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSBBBG00000004005
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSBBBG00000019618
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSBBBG00000016218
Gene Symbol: PLA2G10
1 Cross references
250 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).